Weekly Digest – October 2024 Weekly Digest – October 2024 1 Oct 2024: Enhertu receives priority review in the US for HER2-Low and HER2-Ultralow metastatic breast cancer patients previously treated with endocrine therapy Enhertu (trastuzumab deruxtecan) has been granted Priority […]
Weekly Digest – October 2024 Weekly Digest – October 2024 30 Sep 2024: EMA recommends approval of Mirvetuximab Soravtansine for marketing authorization EMA’s CHMP recommended marketing authorization for Mirvetuximab Soravtansine (Elahere), targeting FRα-positive epithelial ovarian, fallopian tube, and primary peritoneal […]
Weekly Digest – September 2024 Weekly Digest – September 2024 24 Sep 2024: Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) Araris Biotech has […]
Weekly Digest – September 2024 Weekly Digest – September 2024 23 Sep 2024: AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble AstraZeneca and Daiichi Sankyo’s Dato-DXd missed its overall survival goal in […]
